LSD for Schizophrenia

11 papers and 0 clinical trials exploring lsd as a treatment for schizophrenia.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM-120 have reignited clinical development.

Full LSD profile

IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

11 papers

Open Accessindividual

Inter-individual variability in neural response to low doses of LSD

In a placebo-controlled trial of repeated low-dose LSD (N = 53), acute effects included reduced resting EEG delta/theta/alpha power and enhanced pre-attentive processing, plus blunted visual LTP after repeated dosing, and these effects depended on baseline cognitive state — stimulatory effects were largest in participants with low baseline arousal/attention while inhibitory effects were greatest in high memory performers. Decreases in delta power and enhanced pre-attentive processing persisted at 1-week follow-up, suggesting short-term neuroadaptations beyond treatment.

Published: July 15, 2024
Journal: Translational Psychiatry
Authors: Bonnelle, V., Duthaler, U., Feilding, A., Hutten, N. P. W., Kuypers, K. P. C., Liechti, M. E., Mason, N. L., Quaedflieg, C. W. E. M., Ramaekers, J. G., Theunissen, E. L.

Open Accessindividual

Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT-A retrospective case study

This case study (n=1) describes how a teenager self-treated their psychosis (accompanied by complex PTSD and suicidal ideations) through high-dose LSD and low-dose DMT sessions. The hypothesis argues that psychedelics were able to break down the defensive system and allow for the integration of traumatic memories.

Published: December 1, 2022
Journal: Psychiatry Research
Authors: Turkia, M.

Open Accessindividual

Psychedelics and schizophrenia: Distinct alterations to Bayesian inference

This analysis of neuroimaging (M/EEG) compares data from patients with schizophrenia (n=29) and healthy volunteers under the influence of LSD (75μg, n=17) or ketamine (n=19). It finds that although both show increased neural signal diversity, only for those with schizophrenia did it increase the precision (weighting) of sensory information. Both groups increase 'bottom-up' signalling, but of a different kind.

Published: November 1, 2022
Journal: NeuroImage
Authors: Rajpal, H., Mediano, P. A. M., Rosas, F. E., Timmermann, C. B., Brugger, S., Muthukumaraswamy, S., Seth, A. K., Bor, D., Carhart-Harris, R. L., Jensen, H. J.

Open Accessmeta

Default Mode Network Modulation by Psychedelics: A Systematic Review

This systematic review shows that classical psychedelics (LSD, psilocybin, ayahuasca) consistently cause acute disruption of resting-state connectivity within the Default Mode Network and increase cross-network functional connectivity, but it remains unclear how central DMN modulation is to their therapeutic effects. The article synthesises existing evidence and highlights gaps to guide future mechanistic research.

Published: October 22, 2022
Journal: International Journal of Neuropsychopharmacology
Authors: Castle, D., Downey, L., Galvão-Coelho, N. L., Gattuso, J. J., Hoyer, D., Jacobson, L. H., Lawrence, A. J., Nutt, D. J., Pagni, B. A., Perkins, D., Rossell, S. L., Ruffell, S. G. D., Sarris, J., Timmermann, C.

Open Accessmeta

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

This review of recent fMRI studies finds that acute LSD produces widespread alterations in functional brain connectivity — predominantly increases and most consistently heightened thalamocortical coupling — supporting models of reduced cerebral filtering of external and internal information, though results are tempered by neuroimaging limitations and potential biases.

Published: September 30, 2019
Journal: Swiss Medical Weekly
Authors: Felix, M., Stefan, B.

Open Accessmeta

Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

This systematic review of case reports found that psychotic episodes following ayahuasca or DMT use are rare but have been documented in both ritual and recreational/non‑controlled settings. Most reported cases involved a personal or family history of psychosis, bipolar/manic disorders or concomitant substance use, supporting psychiatric screening before administration and avoidance of hallucinogens in those with such histories.

Published: February 23, 2017
Journal: Therapeutic Advances in Psychopharmacology
Authors: Bouso, J. C., Dos Santos, R. G., Hallak, J. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Schizophrenia trials Full LSD profile Full Schizophrenia profile

LSD for Schizophrenia

LSD

Schizophrenia

Academic Research

Inter-individual variability in neural response to low doses of LSD

Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT-A retrospective case study

Psychedelics and schizophrenia: Distinct alterations to Bayesian inference

Default Mode Network Modulation by Psychedelics: A Systematic Review

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

Clinical Trials

Explore further

Company

Product

Legal